These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 16807250)
1. Benefits and concerns of simplification strategies in HIV-infected patients. Negredo E; Bonjoch A; Clotet B J Antimicrob Chemother; 2006 Aug; 58(2):235-42. PubMed ID: 16807250 [TBL] [Abstract][Full Text] [Related]
2. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience. Joly V; Yeni P Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761 [TBL] [Abstract][Full Text] [Related]
3. Once-daily dosing of nevirapine in HAART. Clotet B J Antimicrob Chemother; 2008 Jan; 61(1):13-6. PubMed ID: 18006524 [TBL] [Abstract][Full Text] [Related]
4. Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and ensure adherence avoiding PI use. Barreiro P; García-Benayas T; Soriano V; Gallant J AIDS Rev; 2002; 4(4):233-41. PubMed ID: 12555697 [TBL] [Abstract][Full Text] [Related]
6. Long-Term suppression of HIV infection: benefits and limitations of current treatment options. Sension MG J Assoc Nurses AIDS Care; 2007; 18(1 Suppl):S2-10. PubMed ID: 17275719 [TBL] [Abstract][Full Text] [Related]
7. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients? Cuzin L; Allavena C; Morlat P; Dellamonica P AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976 [TBL] [Abstract][Full Text] [Related]
8. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV. Palma P; Romiti ML; Cancrini C; Pensieroso S; Montesano C; Santucci MB; Bernardi S; Martino AM; Rossi P; Castelli-Gattinara G AIDS; 2007 Nov; 21(18):2465-72. PubMed ID: 18025883 [TBL] [Abstract][Full Text] [Related]
9. [Antiretroviral therapy 2001. Basic principles and current status]. Jablonowski H MMW Fortschr Med; 2001 Apr; 143 Suppl 1():4-12. PubMed ID: 11373777 [TBL] [Abstract][Full Text] [Related]
10. Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens. Sarmati L; Parisi SG; Nicastri E; d'Ettorre G; Andreoni C; Dori L; Gatti F; Montano M; Buonomini AR; Boldrin C; Palù G; Vullo V; Andreoni M J Med Virol; 2007 Jul; 79(7):880-6. PubMed ID: 17516532 [TBL] [Abstract][Full Text] [Related]
11. The rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens. Arribas JR J Antimicrob Chemother; 2004 Sep; 54(3):587-92. PubMed ID: 15282236 [TBL] [Abstract][Full Text] [Related]
12. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903 [TBL] [Abstract][Full Text] [Related]
13. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Jaspan HB; Berrisford AE; Boulle AM Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556 [TBL] [Abstract][Full Text] [Related]
14. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. Bartlett JA; Fath MJ; Demasi R; Hermes A; Quinn J; Mondou E; Rousseau F AIDS; 2006 Oct; 20(16):2051-64. PubMed ID: 17053351 [TBL] [Abstract][Full Text] [Related]
15. Once-daily therapies. Carey D J HIV Ther; 2003 Feb; 8(1):7-11. PubMed ID: 12840708 [TBL] [Abstract][Full Text] [Related]
16. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India. Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504 [TBL] [Abstract][Full Text] [Related]
17. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124 [TBL] [Abstract][Full Text] [Related]